美国血液透析机构间西那卡塞处方差异
研究基于2014年DOPPS数据,描述美国203家透析机构(10,521例患者)的西那卡塞处方分布,并分析机构层面因素与处方率的关系。结果显示机构平均处方率为23%,黑人患者比例高、年龄<65岁及透析龄≥3年比例高的机构处方率更高,但调整患者层面因素后差异显著减弱。
要点
- 美国透析机构西那卡塞处方率差异大,平均23%,中位22%。
- 黑人比例、年轻及透析龄长的机构处方率更高。
- 调整患者病例组合后,机构间差异明显减弱。
核心结论
- 治疗更多黑人、<65岁及透析龄≥3年患者的机构西那卡塞处方率更高,但差异主要源于患者病例组合不平衡。
研究设计与样本
- 横断面研究,使用2014年DOPPS月度数据,纳入203家美国血液透析机构共10,521例患者。
主要发现
- 2014年6月各机构西那卡塞处方平均百分比为23%(中位22%,IQR 13%-30%)。
- 调整机构及非暴露患者变量后,黑人比例最高与最低四分位机构处方率差7.8%(95%CI 0.8%-14.8%,P趋势=0.03)。
- 年龄<65岁比例最高与最低四分位机构处方率差7.3%(95%CI -0.1%-14.7%,P趋势=0.06)。
- 透析龄≥3年比例最高与最低四分位机构处方率差11.9%(95%CI 2.4%-21.4%,P趋势=0.02)。
关键数值与推荐
- 原文未报告指南或共识推荐条款。
临床怎么用
- 临床解读机构西那卡塞处方差异时需考虑患者病例组合,而非直接归因于机构实践差异。
局限性
- 原文未明确报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Calcimimetic drugs used to treat secondary hyperparathyroidism are being considered for inclusion in the Medicare ESRD Prospective Payment System bundle after an evaluation period. Understanding of utilization patterns of calcimimetics across dialysis facilities may help align financial incentives with clinical objectives. Our study's purpose was to describe the distribution of cinacalcet prescription across United States hemodialysis facilities and to explore factors that may influence cinacalcet utilization. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We used monthly cross-sectional data from the Dialysis Outcomes and Practice Patterns Study in 2014 to characterize the distribution of cinacalcet prescription across 203 United States hemodialysis facilities (10,521 patients). On the basis of associations with parathyroid hormone levels from patient-level analyses, we used linear mixed-effects regressions to estimate the associations between three facility-level exposures (black race, <65 years old, and having ≥3 years on dialysis [vintage]) and the prevalence of cinacalcet prescription, adjusting for facility- and patient-level potential confounders. RESULTS: The mean percentage of patients in each facility with cinacalcet prescription was 23% in June 2014 (median, 22%; interquartile range, 13%-30%). Adjusted for facility-level and nonexposure patient-level variables, the difference in prevalence of cinacalcet prescription between facilities with the highest and lowest quartiles of percentage of black patients was 7.8% (95% confidence interval [95% CI], 0.8% to 14.8%; P for trend =0.03). The adjusted prevalence difference was 7.3% for the percentage of patients aged <65 years (95% CI, -0.1% to 14.7%; P for trend =0.06) and 11.9% for the percentage of patients with ≥3 years of dialysis (95% CI, 2.4% to 21.4%; P for trend =0.02). These associations changed appreciably, becoming much weaker or even reversing, after further adjusting for the patient-level exposure variables. CONCLUSIONS: Facilities treating more patients who are black, under age 65 years, and having dialysis vintage ≥3 years have higher average levels of cinacalcet prescription. However, these differences were strongly attenuated after accounting for the unbalanced distributions of these patient case-mix variables.
引用
- Fuller DS, Xing S, Belozeroff V, et al. Variability in Cinacalcet Prescription across US Hemodialysis Facilities. Clin J Am Soc Nephrol. 2019. PMID: 30665922. doi:10.2215/CJN.09550818
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。